Thirty healthy adults consumed 500 mg of a yeast-derived postbiotic fermentate or placebo during two separate visits. Blood was collected at baseline and one, two and three hours later.

The observed profile included selective changes in IFN-gamma, IL-1ra, IL-4, IL-7 and IL-8 at specific time points and a transient redistribution of CD25-positive cells. Authors describe coordinated modulation rather than indiscriminate down-regulation.

The findings can support hypotheses and biomarker selection for later studies. They do not show that one dose prevents infection or improves real-world immune function; clinical endpoints and longer follow-up remain necessary.

Why it matters

For postbiotics, tightly timed endpoints can strengthen a mechanistic rationale and make scientific communication more specific.

Evidence limit

A small acute biomarker study. It does not demonstrate fewer infections, a clinical benefit or a persistent effect over time.

Editorial note. This content is intended for industry professionals. It does not constitute medical advice, therapeutic guidance or regulatory advice. Read our editorial method.

Read the original source · Frontiers in Nutrition ↗